Immunotherapies for Childhood Cancer
Cold Spring Harbor Perspectives in Medicine · 2025
DOI: 10.1101/cshperspect.a041574 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cold Spring Harbor Perspectives in Medicine, 2025. Verfasst von Jeong A Park und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Inha University Hospital, Inha University College of Medicine, Incheon, Korea. Hauptthemen laut MEDLINE: Immunotherapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neuroblastoma, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Children are surviving cancer in greater numbers than ever. Over the last 50 years, substantial advancements in pediatric cancer treatment have resulted in an 85% 5-year survival rate. Nonetheless, a notable 10%-15% of patients encounter relapse or develop refractory disease, leading to significantly lower survival. Recent attempts to further intensify cytotoxic chemotherapy have failed due to either severe toxicities or ineffectiveness, highlighting the need for new treatment strategies. Immunotherapies are emerging and expanding their clinical application to a wide array of cancers, including those affecting children. In pediatric cancers, monoclonal antibodies targeting GD2 have demonstrated durable radiographic and histologic responses in neuroblastoma (NB), and CD19-targeted bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T cells have likewise changed the outlook for refractory acute lymphoblastic leukemia (ALL) in children. This review discusses the clinical development of immunotherapies for pediatric cancers, focusing on pediatric ALL and NB, two major pediatric cancers transformed by immunotherapy, updates on the recent advancements in immunotherapies, and further discusses the future directions of immunotherapy for pediatric cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA cheungn@mskcc.org.
ORCID-Profile: Nai-Kong V Cheung
Förderung
- NCI NIH HHS
Zitieren
APA
Park, J. A., & Cheung, N. V. (2025). Immunotherapies for Childhood Cancer. Cold Spring Harbor Perspectives in Medicine. https://doi.org/10.1101/cshperspect.a041574
Vancouver
Park JA, Cheung NV. Immunotherapies for Childhood Cancer. Cold Spring Harbor Perspectives in Medicine. 2025. doi:10.1101/cshperspect.a041574
BibTeX
@article{Park2025,
author = {Park, Jeong A and Cheung, Nai-Kong V},
title = {Immunotherapies for Childhood Cancer},
journal = {Cold Spring Harbor Perspectives in Medicine},
year = {2025},
doi = {10.1101/cshperspect.a041574}
}
EUVIMED